The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilised cake or powder |
| Solubility class | Freely soluble in water | Aqueous buffers also used |
| Typical storage temperature | About -20 degrees Celsius | Dry, sealed and protected from light |
| Typical analytical method | Reversed-phase HPLC or LC-MS/MS | Used for purity, identity and quantification |
| Common synonyms | Thymosin beta-4 fragment | Also listed under fragment-based descriptions |
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
== Lead-212 == Lead-212 (212Pb) is a radioactive isotope of lead that has gained significant attention in nuclear medicine, particularly in targeted alpha therapy (TAT). This isotope is part of the thorium decay series and serves as an important intermediate in various radioactive decay chains. 212Pb is produced through the decay of radon-220 (220Rn), an intermediate product of thorium-228 (228Th) decay. It undergoes radioactive decay through beta emission to form bismuth-212 (212Bi), which further decays to emit alpha particles. This decay chain is particularly important in medical applications, as it is an in-vivo generator system of alpha particles, that can be utilized for therapeutic purposes, particularly TAT, by delivering potent, localized radiation to cancer cells. The isotope is part of the thorium decay series, which begins with natural thorium-232. Its beta decay (10.627 hours) results in the formation of bismuth-212 (212Bi), which then emits alpha particles (6.1 MeV), crucial for the effectiveness of TAT in cancer treatment. While in aqueous solutions, free Pb2+ tends to hydrolyze under physiological pH conditions to form species like Pb(OH)+, which can impact its biodistribution if not properly chelated, chelator-modified complexes have demonstrated high stability in saline and serum environments for extended periods (e.g., 24–72 hours), which is critical for therapeutic applications. Lead-212 can be synthesized through several methods, with generator-based production utilizing the decay of 228Th being the most common.
== Electrochemistry == The electrochemical reactants in a lithium-ion cell are the materials of the electrodes, both of which are compounds containing lithium atoms. Although many thousands of different materials have been investigated, only a very small number are commercially usable. All commercial Li-ion cells use intercalation compounds as active materials. The negative electrode is usually graphite, although silicon is often mixed in to increase the capacity. The electrolyte is usually lithium hexafluorophosphate, dissolved in a mixture of organic carbonates. A number of different materials are used for the positive electrode, such as LiCoO2, LiFePO4, and lithium nickel manganese cobalt oxides. During cell discharge the negative electrode is the anode and the positive electrode the cathode: electrons flow from the anode to the cathode through the external circuit. An oxidation half-reaction at the anode produces positively charged lithium ions and negatively charged electrons. The oxidation half-reaction may also produce uncharged material that remains at the anode. Lithium ions move through the electrolyte; electrons move through the external circuit toward the cathode where they recombine with the cathode material in a reduction half-reaction. The electrolyte provides a conductive medium for lithium ions but does not partake in the electrochemical reaction. The reactions during discharge lower the chemical potential of the cell, so discharging transfers energy from the cell to wherever the electric current dissipates its energy, mostly in the external circuit.
== San Diego Chargers == The nickname "Fearsome Foursome" was used to describe the early 1960s American Football League's San Diego Chargers' defensive front four. One report is the nickname was originally used for the Chargers line by the team's press agent Bob Burdick, in 1963. The Fearsome Foursome name, however, was used by at least the early 1962 season for the line consisting of right defensive end Ron Nery, left defensive end Earl Faison, left defensive tackle Bill Hudson and right defensive tackle Ernie Ladd. A November 1961 newspaper article about this same Chargers’ defensive line is entitled “Fearsome Foursome Averages 273”. The Chargers moved from Los Angeles to San Diego in 1961, Faison's and Ladd's rookie season. Faison and Ladd would be the core of the Chargers' Fearsome Foursome from 1961 to 1965. Contract disputes with the Chargers led to Faison and Ladd leaving the team in 1966, with Ladd playing the 1966 season for the Houston Oilers, and Faison playing in only three games for the Chargers before going to the Miami Dolphins. Faison was an AFL All-Star in his first five seasons with the Chargers (1961-65), and was All-AFL every year but 1962. He was the only defensive player to ever win the Associated Press (AP) and The Sporting News AFL Rookie of the Year during the AFL's existence (1960-69), and one of only two defensemen to win United Press International's (UPI) AFL Rookie of the Year. The 6 ft 9 in (2.06 m), 290 lb.
== Signs and symptoms == The signs and symptoms of cholestasis vary according to the cause. In case of sudden onset, the disease is likely to be acute, while the gradual appearance of symptoms suggests chronic pathology. In many cases, patients may experience pain in the abdominal area. Localization of pain to the upper right quadrant can be indicative of cholecystitis or choledocholithiasis, which can progress to cholestasis. Pruritus or itching is often present in many patients with cholestasis. Patients may present with visible scratch marks as a result of scratching. Pruritus is often misdiagnosed as a dermatological condition, especially in patients that do not have jaundice as an accompanying symptom. In a typical day, pruritus worsens as the day progresses, particularly during the evening time. Overnight, pruritus dramatically improves. This cycle can be attributed to an increase in the concentration of biliary elements during the day due to food consumption, and a decline at night. Pruritus is mostly localized to the limbs, but can also be more generalized. The efficacy of naltrexone for cholestatic pruritus suggests involvement of the endogenous opioid system. Many patients may experience jaundice as a result of cholestasis. This is usually evident after physical examination as yellow pigment deposits on the skin, in the oral mucosa, or conjunctiva. Jaundice is an uncommon occurrence in intrahepatic (metabolic) cholestasis, but is common in obstructive cholestasis. The majority of patients with chronic cholestasis also experience fatigue.
Sources: en.wikipedia.org
==== Moxibustion and cupping ==== Four adverse events associated with moxibustion were bruising, burns and cellulitis, spinal epidural abscess, and large superficial basal cell carcinoma. Ten adverse events were associated with cupping. The minor ones were keloid scarring, burns, and bullae; the serious ones were acquired hemophilia A, stroke following cupping on the back and neck, factitious panniculitis, reversible cardiac hypertrophy, and iron deficiency anemia.
Boswellia frereana grows in northern Somalia. Boswellia occulta: Somalia. For a long time Somali harvesters considered Boswellia occulta to be the same species as Boswellia carteri even though their shapes are different, and sold resins from both species as the same thing. However in 2019, it was clear that the chemical compositions of their essential oils are completely different. Boswellia sacra: Somalia, South Arabia. Boswellia bhaw-dajiana (older spelling Boswellia bhau-dajiana) It is a synonym of Boswellia sacra Boswellia carteri (older spelling Boswellia carterii): It was long considered an independent species, but in the 1980s it was determined to be a synonym of Boswellia sacra. Boswellia serrata (synonym Boswellia thurifera): India. Boswellia papyrifera: Ethiopia, Eritrea, Sudan. Recent studies indicate that frankincense tree populations are declining, partly from overexploitation. Heavily tapped trees produce seeds that germinate at only 16% while seeds of trees that had not been tapped germinate at more than 80%. In addition, burning, grazing, and attacks by the longhorn beetle have reduced the tree population. Clearing of frankincense woodlands for conversion to agriculture is also a major threat.
=== Temperature dependence === The Young's modulus of metals varies with the temperature and can be realized through the change in the interatomic bonding of the atoms, and hence its change is found to be dependent on the change in the work function of the metal. Although classically, this change is predicted through fitting and without a clear underlying mechanism (for example, the Watchman's formula), the Rahemi-Li model demonstrates how the change in the electron work function leads to change in the Young's modulus of metals and predicts this variation with calculable parameters, using the generalization of the Lennard-Jones potential to solids. In general, as the temperature increases, the Young's modulus decreases via
Sources: en.wikipedia.org
Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.
Reported purity reflects the batch tested, the chromatographic method used and whether an independent laboratory performed the work. Values quoted without method detail or a traceable certificate are difficult to compare directly.
Short peptides are rapidly broken down by proteases and appear at low concentrations in urine, so the detection window is narrow. Sensitive extraction combined with tandem mass spectrometry is typically required.
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.